Marksans Pharma inches up as its arm gets Marketing Authorisation for Levetiracetam Relonchem Oral Solution

28 May 2024 Evaluate

Marksans Pharma is currently trading at Rs. 164.90, up by 0.30 points or 0.18% from its previous closing of Rs. 164.60 on the BSE.

The scrip opened at Rs. 167.90 and has touched a high and low of Rs. 169.20 and Rs. 162.85 respectively. So far 52663 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 185.40 on 18-Apr-2024 and a 52 week low of Rs. 73.25 on 30-May-2023.

Last one week high and low of the scrip stood at Rs. 174.60 and Rs. 161.10 respectively. The current market cap of the company is Rs. 7590.49 crore.

The promoters holding in the company stood at 43.85%, while Institutions and Non-Institutions held 20.74% and 35.40% respectively.

Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization for the product Levetiracetam Relonchem 100 mg/mL Oral Solution from UK Medicines and Healthcare products Regulatory Agency (MHRA). The product will be manufactured at the Group’s UK manufacturing facility. 

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.


Marksans Pharma Share Price

308.55 -0.45 (-0.15%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.